Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director · See Remarks | May 19, 2026 | May 19, 2026 |
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Director · CEO | August 11, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date May 19, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,153,962 |
Ending reported balance
After 2026-05-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-19 · Grant · Acquired 600,118 · Balance 600,118 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Row 2 · 2026-05-19 · Grant · Acquired 553,844 · Balance 1,153,962 F2: These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2036-05-19 | Direct | 2,169,103 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 2,169,103 · Balance 2,169,103 F3: The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
F2: These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration.
F3: The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 2,333 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 2,333 · Balance 2,333 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Third Harmonic Bio, Inc.
Report date August 11, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 1
1 source rowRow 1 · 2025-08-11 · Other · Disposed 1,218,836 · Balance 0 F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-11 · Other · Disposed 998,854 · Balance 0 F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-11 · Other · Disposed 50,000 · Balance 0 F4: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.
F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.
F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.
F4: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allakos Inc.
Report date May 25, 2021 · Filed October 14, 2021
Section 16 reporting ended · disclosed 2021-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.83 · Expires 2031-05-25 | Direct | 7,700 |
Reported balance
After 2021-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 7,700 · Balance 7,700 F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 104,439 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.76 · Expires 2025-11-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Disposition to issuer · Disposed 110,703 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-18 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 548 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2027-01-25 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 40,883 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2027-11-16 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 93,109 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.39 · Expires 2028-05-07 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-15 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-15 · Disposition to issuer · Disposed 50,105 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 57,310 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 40,300 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-06-20 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 28,700 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The options are fully vested.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F7: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F8: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 22:34 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 2,333 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001580111-26-000010 · form4-06242026_100652.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,333 Underlying: Common Stock · 2,333 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:59 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 2,169,103 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001580111-26-000009 · ownership.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,169,103 Underlying: Common Stock · 2,169,103 shares Expires 2036-05-19 F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on April 30, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:59 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 553,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001580111-26-000009 · ownership.xml · nonDerivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,962 F2 · shares: These shares were acquired pursuant to a performance RSU ("PRSU") award as Inducement Awards. The PRSUs are subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on April 15, 2027, subject to Ms. Holles' continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs is the earlier of (i) the sixth (6th) anniversary of the grant date and (ii) the date Ms. Holles no longer has a service relationship with the Issuer. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration. Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:59 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 600,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001580111-26-000009 · ownership.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,118 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award as Inducement Awards. Each RSU represents the right to receive one share of the Issuer's common stock. These RSUs vest in four substantially equal annual installments beginning on April 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| May 05, 2026 Filed May 8, 2026 00:27 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001580111-26-000007 · form4-05082026_120559.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2036-05-04 F1 · derivative.exercise_date: The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerRestricted Stock Unit (RSU) · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 8 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F8 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 22,500 | Not disclosed Strike: $7.01 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 7 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2035-06-01 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 32,335 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 6 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 37,500 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 5 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 28,700 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 4 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 40,300 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,300 shares Expires 2031-05-25 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 40,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:37 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerCommon Stock | 57,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001580111-26-000001 · form4-04232026_080421.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 32,335 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 10 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,335 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 32,335 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 9 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 37,500 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 8 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 37,500 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 7 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 28,700 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 6 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 28,700 | $0.00 Strike: $16.29 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 5 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 40,300 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 4 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,300 Underlying: Common Stock · 40,300 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 40,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,300 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 40,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:14 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 40,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001580111-25-000003 · form4-11072025_111135.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 16:09 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | OtherRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-021825 · form4-08142025_080802.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_price: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F1 · kind: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F4 · derivative.exercise_date: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. F4 · derivative.expiration_date: The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 16:09 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | OtherStock Option · Derivative | 998,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-021825 · form4-08142025_080802.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 998,854 shares Expires not disclosed F3 · derivative.exercise_price: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. F1 · kind: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F3 · derivative.exercise_date: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. F3 · derivative.expiration_date: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 16:09 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | OtherCommon Stock | 1,218,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021825 · form4-08142025_080802.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F2 · price: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantDeferred Restricted Stock Unit (RSU) · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015620 · form4-06042025_090648.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 22,500 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001415889-25-015620 · form4-06042025_090648.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-01 F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 18:03 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001719 · form4-01172025_110140.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F4 · derivative.exercise_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. F4 · derivative.expiration_date: The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 18:03 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001719 · form4-01172025_110140.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-01-14 F1 · kind: The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025. F2 · derivative.exercise_date: The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 22:21 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 32,335 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001415889-24-014714 · form4-05282024_100500.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,335 Underlying: Common Stock · 32,335 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 09, 2024 Filed May 10, 2024 16:04 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,222 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001415889-24-012841 · form4-05102024_080532.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,854 Underlying: Common Stock · 20,222 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| May 09, 2024 Filed May 10, 2024 16:04 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 20,222 | $12.18 | $246,299.92 |
DisclosureSEC source: 0001415889-24-012841 · form4-05102024_080532.xml · nonDerivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,218,836 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2024 Filed May 10, 2024 16:04 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 20,222 | $4.20 | $84,932.40 |
DisclosureSEC source: 0001415889-24-012841 · form4-05102024_080532.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,239,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 16:14 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,558 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001415889-24-010808 · form4-04152024_080410.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,076 Underlying: Common Stock · 13,558 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 16:14 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | SaleCommon Stock | 13,558 | $12.19 | $165,213.72 |
DisclosureSEC source: 0001415889-24-010808 · form4-04152024_080410.xml · nonDerivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,218,836 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on [Month XX, 2023]. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 16:14 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Exercise / conversionCommon Stock | 13,558 | $4.20 | $56,943.60 |
DisclosureSEC source: 0001415889-24-010808 · form4-04152024_080410.xml · nonDerivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,232,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 17:14 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 396,000 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0001209191-24-001055 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests over a four-year period: 1/48th on February 5, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 16:08 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 396,000 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0001209191-24-001236 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests over a four-year period: 1/48th on February 5, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantDirector Stock Option (Right to buy Common Stock) · Derivative | 37,500 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0001209191-23-039810 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 22, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-017243 · doc4.xml · derivative · entry 5 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2033-03-05 F4 · derivative.exercise_date: The option vests over a four-year period: 1/48th on April 6, 2023, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 205,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-017243 · doc4.xml · derivative · entry 4 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2032-10-24 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 205,000 | Not disclosed Strike: $18.40 | Not disclosed |
DisclosureSEC source: 0001209191-23-017243 · doc4.xml · derivative · entry 3 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 205,000 shares Expires 2032-10-24 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a four-year period: 1/48th on November 25, 2022, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Stock Option (right to buy) · Derivative | 467,634 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-017243 · doc4.xml · derivative · entry 2 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,634 Underlying: Common Stock · 467,634 shares Expires 2032-02-16 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 17:05 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 467,634 | Not disclosed Strike: $9.22 | Not disclosed |
DisclosureSEC source: 0001209191-23-017243 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 467,634 shares Expires 2032-02-16 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 16:52 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantEmployee Option Grant (right to buy) · Derivative | 205,000 | $0.00 Strike: $18.40 | $0.00 |
DisclosureSEC source: 0001209191-22-054727 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2032-10-24 F1 · derivative.exercise_date: The option vests over a 6-month period: 1/6th on October 25, 2022, after which 1/6th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 22:11 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantDirector Stock Option (Right to buy Common Stock) · Derivative | 28,700 | $0.00 Strike: $16.29 | $0.00 |
DisclosureSEC source: 0001209191-22-039050 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Stock · 28,700 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares on each monthly anniversary, beginning on July 21, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:33 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-22-003010 · edgar.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| May 25, 2021 Filed Oct 14, 2021 16:29 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 7,700 | $0.00 Strike: $99.83 | $0.00 |
DisclosureSEC source: 0001209191-21-060469 · doc4.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2031-05-25 F1 · derivative.exercise_date: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next Annual Meeting that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.25 | $0.00 |
DisclosureSEC source: 0001179110-21-005312 · edgar.xml · derivative · entry 1 Holles Natalie C. · CIK 0001580111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.